翻译的对吗？

The safety of prescribing angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) on the day of surgery is unclear. In a pooled analysis of 3 small randomized trials including 188 participants, perioperative continuation of ACEIs or ARBs was associated with increased rates of intraoperative hypotension (57.8% vs 23.5% in those who discontinued use of ACEIs or ARBs; pooled relative risk, 2.53 [95% CI, 1.08-5.93]).In a large observational study of 4802 individuals undergoing noncardiac surgery, perioperative discontinuation of ACEIs or ARBs prior to surgery was associated with a lower risk of perioperative hypotension (23.3% vs 28.6% in those with continued use of ACEIs or ARBs;adjusted relative risk, 0.80 [95% CI, 0.73-0.88]) and with a lower risk of the composite end point of myocardial injury after noncardiac surgery, stroke, and mortality at 30 days (12.0% vs 12.9%, respectively; adjusted relative risk, 0.82 [95% CI, 0.70-0.96]).

在手术当天使用血管紧张素转换酶抑制剂（ACEIs）或血管紧张素受体阻滞剂（ARBs）的安全性尚不清楚。在一项包括188名参与者的3个小型随机试验的汇总分析中，围手术期继续使用ACEIs或ARBs与术中低血压发生率的增加有关（57.8% vs 停用ACEIs或ARBs的患者为23.5%；合并相对风险，2.53 [95% CI，1.08-5.93]）。在一项对4802名接受非心脏手术的患者进行的大型观察研究中，术前停用ACEIs或ARBs与围术期低血压风险降低相关（持续使用ACEIs或ARBs的患者为23.3% vs 28.6%；调整后的相对风险为0.80[95%CI，0.73-0.88]，并且非心脏手术后心肌损伤、中风和30天死亡率的复合终点事件风险较低（分别为12.0%和12.9%；调整后的相对风险为0.82[95%CI，0.70-0.96]）。